CoChat

Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort Study

Weber‐Schoendorfer, Corinna, Chambers, Christina, Wacker, Evelin, Beghin, Delphine, Bernard, Nathalie, on behalf of the Network of French Pharmacovigilance Centers, Shechtman, Svetlana, Johnson, Diana, Cuppers‐Maarschalkerweerd, Benedikte, Pistelli, Alessandra, Clementi, Maurizio, Winterfeld, Ursula, Eleftheriou, Georgios, Pupco, Anna, Kao, Kelly, Malm, Heli, Elefant, Elisabeth, Koren, Gideon, Vial, Thierry, Ornoy, Asher, Meister, Reinhard, Schaefer, Christof · 2014 · Arthritis & Rheumatology
Cited by 209

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objective: High‐dose methotrexate (MTX) exposure during pregnancy is associated with embryopathy. The teratogenic potential of MTX at dosages typically used in the treatment of rheumatic diseases remains uncertain. The aim of this study was to evaluate the risk of spontaneous abortion, major birth defects, elective termination of pregnancy, shortened gestational age at delivery, and reduced birth weight in women exposed to MTX. Methods: Pregnancy outcome in women taking MTX (≤30 mg/week) either after conception or within the 12 weeks before conception was evaluated in a prospective observational multicenter cohort study. Pregnancy outcomes in the MTX group were compared to outcomes in a group of disease‐matched women and a group of women without autoimmune diseases (neither group was exposed to MTX). Results: The study sample included 324 MTX‐exposed pregnancies (188 exposed post‐conception, 136 exposed pre‐conception), 459 disease‐matched comparison women, and 1,107 comparison women without autoimmune diseases. In the post‐conception cohort, the cumulative incidence of spontaneous abortion was 42.5% (95% confidence interval [95% CI] 29.2–58.7), which was significantly higher than the incidence of spontaneous abortion in either comparison group. The risk of major birth defects (7 of 106 [6.6%]) was elevated compared to both the cohort of women without autoimmune diseases (29 of 1,001 [2.9%]) (adjusted odds ratio [OR] 3.1 [95% CI 1.03–9.5]) and the disease‐matched cohort (14 of 393 [3.6%]) (adjusted OR 1.8 [95% CI 0.6–5.7]). None of the malformations were clearly consistent with MTX embryopathy. Neither the cumulative incidence of spontaneous abortion (14.4% [95% CI 8.0–25.3]) nor the risk of major birth defects (4 of 114 [3.5%]) was increased in the pre‐conception cohort. Elective termination rates were increased in both of the MTX‐exposed cohorts. There were no other significant differences among groups in other study end points. Conclusion: Post‐conception administration of MTX at dosages typically used in the treatment of rheumatic diseases was associated with an increased risk of major birth defects and spontaneous abortion. Such evidence was not found among women in our pre‐conception cohort.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.38368

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Weber‐Schoendorfer, C., Chambers, C., Wacker, E., Beghin, D., Bernard, N., on behalf of the Network of French Pharmacovigilance Centers, Shechtman, S., Johnson, D., Cuppers‐Maarschalkerweerd, B., Pistelli, A., Clementi, M., Winterfeld, U., Eleftheriou, G., Pupco, A., Kao, K., Malm, H., Elefant, E., Koren, G., Vial, T., Ornoy, A., Meister, R., & Schaefer, C.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2014-04-28
Volume
66
Issue
5
Pages
1101-1110
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W1962974240
Cited by
209
References
2
FWCI
17.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.